Taunk Khushman, Jajula Saikiran, Bhavsar Praneeta Pradip, Choudhari Mahima, Bhanuse Sadanand, Tamhankar Anup, Naiya Tufan, Kalita Bhargab, Rapole Srikanth
Proteomics Lab, National Centre for Cell Science, Ganeshkhind, Pune, Maharashtra, 411007, India.
Department of Biotechnology, Maulana Abul Kalam Azad University of Technology, West Bengal, NH12 Simhat, Haringhata, Nadia, West Bengal, 741249, India.
Mol Cell Biochem. 2025 Feb;480(2):693-720. doi: 10.1007/s11010-024-05041-w. Epub 2024 May 30.
Cancer due to its heterogeneous nature and large prevalence has tremendous socioeconomic impacts on populations across the world. Therefore, it is crucial to discover effective panels of biomarkers for diagnosing cancer at an early stage. Cancer leads to alterations in cell growth and differentiation at the molecular level, some of which are very unique. Therefore, comprehending these alterations can aid in a better understanding of the disease pathology and identification of the biomolecules that can serve as effective biomarkers for cancer diagnosis. Metabolites, among other biomolecules of interest, play a key role in the pathophysiology of cancer whose levels are significantly altered while 'reprogramming the energy metabolism', a cellular condition favored in cancer cells which is one of the hallmarks of cancer. Metabolomics, an emerging omics technology has tremendous potential to contribute towards the goal of investigating cancer metabolites or the metabolic alterations during the development of cancer. Diverse metabolites can be screened in a variety of biofluids, and tumor tissues sampled from cancer patients against healthy controls to capture the altered metabolism. In this review, we provide an overview of different metabolomics approaches employed in cancer research and the potential of metabolites as biomarkers for cancer diagnosis. In addition, we discuss the challenges associated with metabolomics-driven cancer research and gaze upon the prospects of this emerging field.
癌症因其异质性和高发病率,对全球人群产生了巨大的社会经济影响。因此,发现用于早期诊断癌症的有效生物标志物组合至关重要。癌症会在分子水平上导致细胞生长和分化的改变,其中一些改变非常独特。因此,理解这些改变有助于更好地了解疾病病理,并识别可作为癌症诊断有效生物标志物的生物分子。代谢物作为其他感兴趣的生物分子之一,在癌症的病理生理学中起着关键作用,其水平在“重编程能量代谢”时会显著改变,“重编程能量代谢”是癌细胞中一种有利的细胞状态,也是癌症的标志之一。代谢组学作为一种新兴的组学技术,在研究癌症代谢物或癌症发展过程中的代谢改变方面具有巨大潜力。可以在各种生物流体中筛选多种代谢物,并从癌症患者身上采集肿瘤组织与健康对照进行比较,以捕捉代谢变化。在这篇综述中,我们概述了癌症研究中采用的不同代谢组学方法以及代谢物作为癌症诊断生物标志物的潜力。此外,我们还讨论了代谢组学驱动的癌症研究相关挑战,并展望了这一新兴领域的前景。